Literature DB >> 28647036

Supra-aortic interventions for endovascular exclusion of the entire aortic arch.

Terézia B Andrási1, Marius Grossmann2, Dieter Zenker2, Bernhard C Danner2, Friedrich A Schöndube2.   

Abstract

OBJECTIVE: Our aim was to analyze the outcomes of endovascular exclusion of the entire aortic arch (proximal landing in zone 0, distal landing in zone III or beyond, after Ishimaru) in which complete surgical debranching of the supra-aortic vessels (I), endovascular supra-aortic revascularization (chimney, fenestrated, or branched grafts) with partial surgical debranching (II), or total endovascular supra-aortic revascularization (III) was additionally performed.
METHODS: Publications describing endovascular repair of the aortic arch (2000-2016) were systematically searched and reviewed.
RESULTS: From a total of 53 relevant studies including 1853 patients, only 1021 patients undergoing 35 different total aortic arch procedures were found eligible for further evaluation and included in group I, II, or III (429, 190, and 402 patients, respectively). Overall early mortality was higher in group I vs groups II and III (P = .001; 1 - β = 95.6%) but exceeded in group III (18.6%) and group II (14.0%) vs group I (8.0%; P = .044; 1 - β = 57.4%) for diseases involving zone 0. Mortality was higher in all subgroups treated for zone 0 disease compared with corresponding subgroups treated for zone I to zone III disease. The incidence of cerebral ischemic events was increased in groups I and II vs group III (7.5% and 11% vs 1.7%; P = .0001) and correlated with early mortality (R2 = .20; P = .033). The incidence of type II endoleaks and endovascular reintervention was similar between groups and correlated with each other (R2 = .37; P = .004). Type Ia endoleak occurred more often in groups II and III than in group I (7.1% and 12.1% vs 5.8%; P = .023) and correlated with midterm mortality (R2 = .53; P = .005). Retrograde type A dissection was low in all groups, whereas aneurysm growth was higher in group III (2.6%, 4.2%, 10.7%; P = .002), correlating with midterm mortality (R2 = .311; P = .009). Surgical revision slightly correlated with surgical complications (R2 = .18; P = .044) but not with mortality (R2 = .10; P = .214).
CONCLUSIONS: Because early mortality was significantly higher in patients receiving endovascular treatment for proximal aortic disease, endovascular-based approaches proved to be feasible alternatives to hybrid surgical procedures, especially when they were performed for aneurysms located in the distal aortic arch. Whereas cerebral ischemia accompanies both surgical and endovascular involvement of the supra-aortic vessels, endoleaks and aneurysm growth remain hallmarks of endovascular supra-aortic repair. Because surgical revision had no impact on mortality, complete surgical debranching may become the option of choice for patients with good life expectancy suffering from proximal aortic arch disease, whereas total endovascular procedures could be particularly advantageous in patients with short life expectancy and distal aortic arch disease.
Copyright © 2017 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28647036     DOI: 10.1016/j.jvs.2017.04.024

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  12 in total

1.  Status of branched endovascular aortic arch repair.

Authors:  Theodorus M van Bakel; Hector W de Beaufort; Santi Trimarchi; Massimiliano M Marrocco-Trischitta; Jean Bismuth; Frans L Moll; Himanshu J Patel; Joost A van Herwaarden
Journal:  Ann Cardiothorac Surg       Date:  2018-05

2.  Cerebral embolic protection during endovascular arch replacement.

Authors:  Christine R Herman; Christian Rosu; Cherrie Z Abraham
Journal:  Ann Cardiothorac Surg       Date:  2018-05

3.  Hybrid repair versus conventional open repair for thoracic aortic arch aneurysms.

Authors:  Ala Elhelali; Niamh Hynes; Declan Devane; Sherif Sultan; Edel P Kavanagh; Liam Morris; Dave Veerasingam; Fionnuala Jordan
Journal:  Cochrane Database Syst Rev       Date:  2021-06-04

4.  Endovascular aortic repairs combined with looping-chimney technique for repairing aortic arch lesions and reconstructing left common carotid artery.

Authors:  Jinhui Zhang; Xunqiang Liu; Min Tian; Huanjun Chen; Jifeng Wang; Min Ji; Lei Cong; Chunxin Yang; Enshuai Zhu; Jing Tan
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 2.895

5.  Anaesthetic management in endovascular total aortic arch repair via needle-based in situ fenestration: a case series of 14 patients.

Authors:  Kui-Rong Wang; Min Gao; Xiao-Hong Wen; Hai-Ying Kong
Journal:  J Int Med Res       Date:  2019-12-26       Impact factor: 1.671

Review 6.  Various Endoluminal Approaches Available for Treating Pathologies of the Aortic Arch.

Authors:  Muzaffar A Anwar; Mohammad Hamady
Journal:  Cardiovasc Intervent Radiol       Date:  2020-06-25       Impact factor: 2.740

7.  Hybrid zone zero debranching thoracic endovascular aortic repair of ascending aortic injury after surgery and radiotherapy for breast cancer.

Authors:  Hiromitsu Teratani; Hitoshi Matsumura; Yuta Sukehiro; Yoshio Hayashida; Noritoshi Minematsu; Hideichi Wada
Journal:  J Vasc Surg Cases Innov Tech       Date:  2020-12-28

8.  A Clampless Aortoprosthetic End to Side Anastomotic Device with Large Diameter Aortic Puncher.

Authors:  Tadahiro Sasajima; Yukihiro Saito; Hayato Ise; Daiki Uchida; Hiroyuki Kamiya
Journal:  EJVES Vasc Forum       Date:  2020-02-27

9.  Hybrid Repair of an Aneurysm of the Innominate Artery.

Authors:  Peter-Jan Vancoillie; Karen Peeters; Sigi Nauwelaers; Luc Stockx; Geert Lauwers
Journal:  EJVES Vasc Forum       Date:  2021-10-08

10.  Anatomic Suitability for Branched Thoracic Endovascular Repair in Patients with Aortic Arch Pathological Features.

Authors:  Stefan P M Smorenburg; Matthew Montesano; Tijs J Hoogteijling; Maarten Truijers; Petr Symersky; Evert K Jansen; Harmen R Zandbergen; Willem Wisselink; Theodorus G van Schaik; Kak Khee Yeung
Journal:  J Am Heart Assoc       Date:  2020-10-03       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.